Michael Andrew Chambers, Director at Sarepta Therapeutics, Inc. (SRPT), bought 74,076 shares at $134.66 ($9.9M) on 2024-08-16, disclosed to the SEC on 2024-08-20.
Open-market purchase of $9.9M SRPT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $133.07 | 13,106 | $1.7M | 17.6% |
| 2 | $133.07 | 13,106 | $1.7M | 17.6% |
| 3 | $134.06 | 18,284 | $2.5M | 24.7% |
| 4 | $134.06 | 18,284 | $2.5M | 24.7% |
| 5 | $134.66 | 5,648 | $761K | 7.7% |
| 6 | $134.66 | 5,648 |
| $761K |
| 7.7% |
| Total | $133.80 avg | 74,076 | $9.9M | 100% |
| Filing → |
| SRPT | BUY | 2023-08-11 | $7.4M | — | Filing → |
| SRPT | BUY | 2022-09-15 | $11.3M | — | Filing → |
| SRPT | BUY | 2022-08-22 | $5.0M | — | Filing → |